Qualigen Therapeutics, Inc (QLGN)

Etorro trading 970x250

About Qualigen Therapeutics, Inc

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011

Qualigen Therapeutics, Inc News and around…

Latest news about Qualigen Therapeutics, Inc (QLGN) common stock and company :

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
20 May, 2022 Yahoo! Finance

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hote

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
18 May, 2022 FinancialContent

Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 17.3% to $0.4 during Wednesday's pre-market session. ...

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
13 May, 2022 Yahoo! Finance

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the first quarter ended March 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments. Corporate Highlights During Q

Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel
10 May, 2022 Yahoo! Finance

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 May, 2022 FinancialContent

Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 72.6% to $143.49 during Tuesday's pre-market ...

Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform
03 May, 2022 FinancialContent

Qualigen Therapeutics Inc(NASDAQ: QLGN) hasagreed to acquire a majority stakeinNanoSynex Ltd, an ...

Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03 May, 2022 Yahoo! Finance

Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has entered into definitive agreements to acquire a majority stake in

20 Stocks Moving in Tuesday's Pre-Market Session
03 May, 2022 FinancialContent

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and ...

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President
29 Apr, 2022 Yahoo! Finance

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company’s newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company’s diagnostics division. “Shishir’s consistent leadership

QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics…
18 Apr, 2022 Yahoo! Finance

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Licenses G4-Selective Transcription Inhibitors to Develop as Cancer Therapeutics In January 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug program from University College London. The lead compound,

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
13 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
12 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. The post Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Apr, 2022 FinancialContent

Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 2670.4% to $3.33 during Tuesday's regular session. Trading volume for this ...

Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers
12 Apr, 2022 FinancialContent

Qualigen Therapeutics Inc(NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer ...

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
12 Apr, 2022 Yahoo! Finance

AACR POSTER Structural and Chemical Biology AACR POSTER - CHART 1 New Chemotherapy Agents AACR POSTER - CHART 2 Tumor Volumes for CTG-1128 AACR POSTER - CHART 3 Tumor Volumes for CTG-0952 AACR POSTER - CHART 4 Tumor Volumes for CTG-2184 Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing tr

Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05 Apr, 2022 Yahoo! Finance

Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the official resumption as of April 1, 2022 of worldwide distribution and commercial control of FastPack® from previous

Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
01 Apr, 2022 Yahoo! Finance

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces its financial results for the fiscal year ended December 31, 2021. “Our financial results for 2021 are highlighted by a 31% increase in revenue over 2020 in our diagnostics business, which includes incr

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
30 Mar, 2022 Yahoo! Finance

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of lead drug candidate QN-302. Qualigen is initially investiga

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference
22 Mar, 2022 Yahoo! Finance

Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today provides data from published abstracts from the American Association of Cancer Research (AACR) demons

Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
15 Mar, 2022 Yahoo! Finance

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the Company’s collaboration with the research institution to develop

12 Health Care Stocks Moving In Wednesday's After-Market Session
02 Mar, 2022 FinancialContent

Gainers Eargo (NASDAQ:EAR) shares rose 10.9% to $5.29 during Wednesday's after-market session. Today's trading volume for this ...

88 Biggest Movers From Yesterday
25 Feb, 2022 FinancialContent

Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million ...

44 Stocks Moving In Thursday's Mid-Day Session
24 Feb, 2022 FinancialContent

Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on ...

32 Stocks Moving in Thursday's Pre-Market Session
24 Feb, 2022 FinancialContent

Gainers Imperial Petroleum Inc.(NASDAQ: IMPP) rose 45.1% to $1.64 in pre-market trading after gaining around 41% on ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
22 Feb, 2022 FinancialContent

Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 30.0% to $2.0 during Tuesday's after-market session. Today's ...

Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
22 Feb, 2022 Yahoo! Finance

CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation and diagnostics, today issues the following Letter to Shareholders: To Our Valued Shareholders: As we close out the second month of 2022, I am excited for what lies ahead for our company. The last 45 days have helped to realize the well-constructed strategy of

Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
15 Feb, 2022 Yahoo! Finance

Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces that three abstracts on aspects of the Company’s recently in-licensed compound from University College -London, QN-302, have been accepted as posters to be

Stocks That Hit 52-Week Lows On Monday
14 Feb, 2022 FinancialContent

During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 ...

Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
01 Feb, 2022 Yahoo! Finance

Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
18 Jan, 2022 Yahoo! Finance

Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data

Qualigen Therapeutics, Inc (QLGN) is a NASDAQ Common Stock listed in , ,

970x250